购物车
- 全部删除
- 您的购物车当前为空
LSD1-IN-34(Compound 7d)作为一种口服活性抑制剂,特异性针对赖氨酸特异性脱甲基酶(LSD)和单胺氧化酶(MAO),其对LSD1和MAO A的IC50值分别为4.51 nM和18.46 nM.该化合物能够有效地阻断血管紧张素 II(Ang II)引起的新生大鼠心肌成纤维细胞(NRCF)的活化,且在20 μM浓度下未见明显毒性.此外,LSD1-IN-34还能够抑制TGFβ/Smad信号通路,从而优化小鼠心力衰竭状况.在大鼠体内的药代动力学表现良好,展现出该化合物的潜在疗效.
LSD1-IN-34(Compound 7d)作为一种口服活性抑制剂,特异性针对赖氨酸特异性脱甲基酶(LSD)和单胺氧化酶(MAO),其对LSD1和MAO A的IC50值分别为4.51 nM和18.46 nM.该化合物能够有效地阻断血管紧张素 II(Ang II)引起的新生大鼠心肌成纤维细胞(NRCF)的活化,且在20 μM浓度下未见明显毒性.此外,LSD1-IN-34还能够抑制TGFβ/Smad信号通路,从而优化小鼠心力衰竭状况.在大鼠体内的药代动力学表现良好,展现出该化合物的潜在疗效.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 期货 | |
50 mg | 询价 | 期货 |
产品描述 | LSD1-IN-34 (Compound 7d) is an orally effective inhibitor of lysine-specific demethylase (LSD) and monoamine oxidase (MAO), exhibiting IC50 values of 4.51 nM for LSD1 and 18.46 nM for MAO A. This compound inhibits activation of neonatal rat cardiac fibroblasts (NRCF) induced by angiotensin II (Ang II) and shows no significant toxicity at 20 μM. LSD1-IN-34 also inhibits the TGFβ/Smad signaling pathway, contributing to the improvement of heart failure in mice. Moreover, it demonstrates favorable pharmacokinetic properties in rats. |
靶点活性 | MAO-B:8481.67 nM, MAO-A:18.46 nM, LSD1:4.51 nM |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容